Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. The Israeli Sprint Study Group.
The efficacy of nifedipine in the prevention of post-infarction morbidity and mortality was evaluated in a double-blind clinical trial of 2276 survivors of acute myocardial infarction recruited from the cardiac departments of 14 Israeli hospitals. The patients were randomized to either nifedipine 30 mg day-1 or placebo between 7 and 21 days after their hospitalization for the acute event. Baseline characteristics of patients in each group were virtually identical for most pertinent variables. Mortality during an average 10-month follow-up period was 5.7% in the placebo group and 5.8% among those receiving nifedipine. Nonfatal recurrent myocardial infarction occurred in 4.8% and 4.4% of placebo and nifedipine patients, respectively. Administration of nifedipine according to the protocol used in the present study had no effect on cardiac events in survivors of acute myocardial infarction.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D009543:Nifedipine / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation; D013997:Time Factors
D010919:Placebos; D009543:Nifedipine